CoChat
Cited by 234

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial

Open access
Robinson, Giles W, Rudneva, Vasilisa A, Buchhalter, Ivo, Billups, Catherine A, Waszak, Sebastian M, Smith, Kyle S, Bowers, Daniel C, Bendel, Anne, Fisher, Paul G, Partap, Sonia, Crawford, John R, Hassall, Tim, Indelicato, Daniel J, Boop, Frederick, Klimo, Paul, Sabin, Noah D, Patay, Zoltan, Merchant, Thomas E, Stewart, Clinton F, Orr, Brent A, Korbel, Jan O, Jones, David T W, Sharma, Tanvi, Lichter, Peter, Kool, Marcel, Korshunov, Andrey, Pfister, Stefan M, Gilbertson, Richard J, Sanders, Robert P, Onar-Thomas, Arzu, Ellison, David W, Gajjar, Amar, Northcott, Paul A · 2018 · The Lancet Oncology

Abstract

Background Young children with medulloblastoma have inferior survival to older children. While the principal difference is due to radiation-sparing therapy, radiation is not an absolute requisite for survival of all. We aimed to estimate the event-free survival of young medulloblastoma patients with a robust sample size using different treatment strategies designed to defer, reduce, or delay radiation exposure. These strategies were deemed reasonable at the start of the trial by physicians and ethics review board. Additionally, we aimed to define the molecular characteristics associated with progression-free survival. Methods In this multicenter phase II trial we enrolled children younger than 3-years-old with newly diagnosed medulloblastoma, supratentorial primitive neuroectodermal tumor, pineoblastoma, atypical teratoid/rhabdoid tumor, high grade glioma, choroid plexus carcinoma, or ependymoma. Children ≥ 3 and < 5-years-old with newly diagnosed non-metastatic medulloblastoma without any high-risk features were also eligible. The study enrolled from 6 participating institutions. Patients were required to start therapy within 31 days from definitive surgery. Eligible patients had to have a Lansky performance score ≥ 30 (except for posterior fossa syndrome) and adequate hematopoietic, renal, and hepatic functions. Patients were ineligible if they had received any prior radiotherapy or chemotherapy. Patients were postoperatively stratified by clinical and histologic criteria into low-, intermediate-, and high-risk groups. All participants received 4 identical cycles of induction chemotherapy with high-risk patients also receiving vinblastine between induction cycles. Induction was followed by risk-adapted consolidation therapy: low-risk patients received a cyclophosphamide (1,500 mg/m2 IV day 1), etoposide (100mg/m2 IV day 1,2), carboplatin (AUC 5mg/mL/min IV day 2) regimen; intermediate-risk patients received focal radiation therapy (54 Gy with a clinical target volume of 5mm) to the tumor bed; and high-risk patients received chemotherapy with targeted IV topotecan (AUC 120-160 ng-hr/mL IV day 1-5) and cyclophosphamide (600mg/m2 IV day 1-5) or optional craniospinal radiation (23.4-39.6 Gy) for those who reach 3-years of age by the end of induction. After consolidation, all patients were to receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan and erlotinib. Per intent to treat all patients who received at least one dose of the first induction chemotherapy (methotrexate) were included in the analysis. Archived tumor specimens were sub-classified into molecular subdivisions based on DNA methylation profiles and overlaid with mutations and copy-number alterations. The co-primary endpoints for the study were (1) therapeutic: to estimate the event-free survival distribution of young medulloblastoma patients treated with risk-adapted therapy, and (2) biologic: to identify patterns of methylation profiling that are associated with progression-free survival among young patients with medulloblastoma treated with risk-adapted therapy. Medulloblastoma accrual drove the primary endpoints of the study it is the only entity discussed here. This trial is registered at ClinicalTrials.gov, number NCT00602667. The trial was permanently closed to accrual in April 2017. Findings Between November 27, 2007 and April 19, 2017, we enrolled 81 patients histopathologically diagnosed with medulloblastoma. All 81 started treatment and were included in the analysis. Accrual to the low-risk arm was suspended December 2, 2015 when the 1-year event-free survival was estimated to be 78.3%; a value below the 80% stopping rule boundary. The trial was closed to accrual once the specified accrual duration was reached. After a median follow up of 5.5 years (IQR 2.7-7.3) the 5-year event-free survival of the low-risk cohort was 55.3% (95% CI 33.3-77.3%); intermediate-risk was 24.6% (95% CI 3.6-45.6%); and high-risk was 16.7% (95% CI 3.4-30.0%) (p=0.0021). Survival by methylation subgroup showed 5-year progression-free survival of sonic hedgehog (SHH) was 51.1% (95% CI 34.6-67.6%) vs 8.3% (95% CI 0.0-24.0%) for group 3 (G3) (p<0.0001) vs 13.3% (95% CI 0.0-37.6%) for group 4 (G4) (p=0.095). The 5-year progression-free survival of two distinct methylation profiling patterns of SHH, medulloblastoma named subtype iSHH-I and iSHH-II, were 27.8% (95% CI 9.0-46.6%) and 75.4% (95% CI 55.0-95.8%), respectively (HR 4.17, 95% CI 1.51-11.53, p=0.0028). The 5-year progression-free survival of low-risk iSHH-II was 90.9% (95% CI 73.1-100.0%) vs 22.2% (95% CI 0.1-44.3%) for iSHH-I (HR 14.75, 95% CI 1.84-118.04, p=0.0007). All three risk-adapted therapies were well tolerated and no protocol-related deaths were observed. The most common adverse events were expected grade 3-4 toxicities including febrile neutropenia (48 patients [59%]), neutropenia (21 [26%]), infection with neutropenia (20 [25%]), leukopenia (15 [19%]), vomiting (15 [19%]) and anorexia (13 [16%]). Interpretation The risk-adapted approach failed to identify an acceptable benefit despite being well-tolerated. However, through the prespecified application of integrative genomics to this clinical trial cohort, we identified a good-responder SHH-subtype (iSHH-II) that exhibits excellent progression-free survival in the absence of radiation, intra-ventricular chemotherapy, or high-dose chemotherapy; a poor-responder SHH-subtype (iSHH-I); and very poor progression-free survival for G3/G4 medulloblastoma. These findings support the development of a molecularly-driven risk-adapted approach that will shape risk stratification and therapy on future medulloblastoma trials for young children. Funding American Lebanese Syrian Associated Charities, St Jude Children’s Research Hospital, NCI Cancer Center Grant (P30CA021765), Alexander and Margaret Stewart Trust, Sontag Foundation, and American Association for Cancer Research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(18)30204-3

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 234

Metadata

Authors
Robinson, G. W., Rudneva, V. A., Buchhalter, I., Billups, C. A., Waszak, S. M., Smith, K. S., Bowers, D. C., Bendel, A., Fisher, P. G., Partap, S., Crawford, J. R., Hassall, T., Indelicato, D. J., Boop, F., Klimo, P., Sabin, N. D., Patay, Z., Merchant, T. E., Stewart, C. F., Orr, B. A., Korbel, J. O., Jones, D. T. W., Sharma, T., Lichter, P., Kool, M., Korshunov, A., Pfister, S. M., Gilbertson, R. J., Sanders, R. P., Onar-Thomas, A., Ellison, D. W., Gajjar, A., & Northcott, P. A.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2018-06
Volume
19
Issue
6
Pages
768-784
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2803132298
Cited by
234
References
3
FWCI
12.51
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(18)30204-3
The paper
Robinson, G. W., Rudneva, V. A., Buchhalter, I., Billups, C. A., Waszak, S. M., Smith, K. S., Bowers, D. C., Bendel, A., Fisher, P. G., Partap, S., Crawford, J. R., Hassall, T., Indelicato, D. J., Boop, F., Klimo, P., Sabin, N. D., Patay, Z., Merchant, T. E., Stewart, C. F., . . . Northcott, P. A. (2018). Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(18)30204-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.